Mottaghy FM - Search Results

1

Labelling via [Al¹⁸F]²⁺ Using Precomplexed Al-NODA Moieties.

Kang D, Simon U, Mottaghy FM, Vogg ATJ. Kang D, et al. Among authors: mottaghy fm. Pharmaceuticals (Basel). 2021 Aug 20;14(8):818. doi: 10.3390/ph14080818. Pharmaceuticals (Basel). 2021. PMID: 34451915 Free PMC article.

2

Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog.

Schmid M, Neumaier B, Vogg AT, Wczasek K, Friesen C, Mottaghy FM, Buck AK, Reske SN. Schmid M, et al. Among authors: mottaghy fm. Nucl Med Biol. 2006 Apr;33(3):359-66. doi: 10.1016/j.nucmedbio.2005.12.010. Epub 2006 Mar 9. Nucl Med Biol. 2006. PMID: 16631084

3

Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia.

Neumaier B, Mottaghy FM, Buck AK, Glatting G, Blumstein NM, Mahren B, Vogg AT, Reske SN. Neumaier B, et al. Among authors: mottaghy fm. Cancer Biother Radiopharm. 2008 Dec;23(6):819-24. doi: 10.1089/cbr.2008.0512. Cancer Biother Radiopharm. 2008. PMID: 19111052

4

Targeted endoradiotherapy using nucleotides.

Morgenroth A, Vogg AT, Mottaghy FM, Schmaljohann J. Morgenroth A, et al. Among authors: mottaghy fm. Methods. 2011 Nov;55(3):203-14. doi: 10.1016/j.ymeth.2011.06.009. Epub 2011 Jul 18. Methods. 2011. PMID: 21782950 Review.

5

Simultaneous dual-isotope SPECT/CT with (99m)Tc- and (111)In-labelled albumin microspheres in treatment planning for SIRT.

Palmowski M, Goedicke A, Vogg A, Christ G, Mühlenbruch G, Kaiser HJ, Günther RW, Kuhl CK, Mottaghy FM, Behrendt FF. Palmowski M, et al. Among authors: mottaghy fm. Eur Radiol. 2013 Nov;23(11):3062-70. doi: 10.1007/s00330-013-2916-9. Epub 2013 Jun 16. Eur Radiol. 2013. PMID: 23771601

6

Nondestructive monitoring of tissue-engineered constructs.

Frese J, Morgenroth A, Mertens ME, Koch S, Rongen L, Vogg AT, Zlatopolskiy BD, Neumaier B, Gesche VN, Lammers T, Schmitz-Rode T, Mela P, Jockenhoevel S, Mottaghy FM, Kiessling F. Frese J, et al. Among authors: mottaghy fm. Biomed Tech (Berl). 2014 Apr 1;59(2):165-75. doi: 10.1515/bmt-2013-0029. Biomed Tech (Berl). 2014. PMID: 24021591

7

Breaking the invulnerability of cancer stem cells: two-step strategy to kill the stem-like cell subpopulation of multiple myeloma.

Morgenroth A, Vogg AT, Zlatopolskiy BD, Siluschek M, Oedekoven C, Mottaghy FM. Morgenroth A, et al. Among authors: mottaghy fm. Mol Cancer Ther. 2014 Jan;13(1):144-53. doi: 10.1158/1535-7163.MCT-13-0240. Epub 2013 Oct 30. Mol Cancer Ther. 2014. PMID: 24174494

8

Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation.

Morgenroth A, Vogg AT, Ermert K, Zlatopolskiy B, Mottaghy FM. Morgenroth A, et al. Among authors: mottaghy fm. Oncotarget. 2014 Jul 30;5(14):5483-93. doi: 10.18632/oncotarget.2123. Oncotarget. 2014. PMID: 24978848 Free PMC article.

9

[(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice.

Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM, Behrendt FF. Krohn T, et al. Among authors: mottaghy fm. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):210-4. doi: 10.1007/s00259-014-2915-3. Epub 2014 Sep 24. Eur J Nucl Med Mol Imaging. 2015. PMID: 25248644

10

Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF. Verburg FA, et al. Among authors: mottaghy fm. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403. doi: 10.1007/s00259-015-3240-1. Epub 2015 Nov 12. Eur J Nucl Med Mol Imaging. 2016. PMID: 26563121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

458 results

Search Page